<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": bold;} span.year {font-family : courier ; font-style : italic;}" exact="Diabetes" post="Metab SyndrDiabetes Metab SyndrDiabetes &amp;amp; Metabolic Syndrome1871-40211878-0334Diabetes India. Published"/>
 <result pre="of therapeutic and other drugs used in Co-morbid diseases (Hypertension," exact="diabetes" post="etc) GuptaRiteshaMisraAnoopanoopmisra@gmail.comabc∗[a], [b], [c], ∗Corresponding author. Fortis CDOC Hospital,"/>
 <result pre="Chirag Enclave, New Delhi, India. anoopmisra@gmail.com pmc-release: 2020-3-3ppub: 2020epub: 2020-3-3143251254(C)" exact="Diabetes" post="India, 2020Since January 2020 Elsevier has created a COVID-19"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
 <result pre="the COVID-19 resource centre remains active. Abstract Background and aims" exact="Multiple" post="issues in management of COVID have emerged, but confusion"/>
 <result pre="active. Abstract Background and aims Multiple issues in management of" exact="COVID" post="have emerged, but confusion persists regarding rational interpretation. Aim"/>
 <result pre="23 March 2020. Search terms were, COVID-19, treatment of coronavirus," exact="COVID" post="19 and following terms; chloroquine, hydroxychloroquine, ibuprofen, ACE-inhibitors or"/>
 <result pre="following terms; chloroquine, hydroxychloroquine, ibuprofen, ACE-inhibitors or angiotensin receptor blockers," exact="cardiovascular disease," post="diarrhoea, liver, testis and gastrointestinal disease. Results We discuss"/>
 <result pre="or angiotensin receptor blockers, cardiovascular disease, diarrhoea, liver, testis and" exact="gastrointestinal disease." post="Results We discuss evidence regarding role of chloroquine and"/>
 <result pre="with co-morbidities are based on current evidence, however, data is" exact="limited" post="and there is immediate need for fast track research."/>
 <result pre="an article highlighting the special concerns while managing patients with" exact="diabetes" post="in the times of severe acute respiratory syndrome coronavirus"/>
 <result pre="while managing patients with diabetes in the times of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of"/>
 <result pre="managing patients with diabetes in the times of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of the"/>
 <result pre="patients with diabetes in the times of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), the etiological agent of the (Corona"/>
 <result pre="syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of the (Corona" exact="Virus Disease" post="2019) COVID-19 pandemic [1]. More data has accumulated since"/>
 <result pre="coronavirus 2 (SARS-CoV-2), the etiological agent of the (Corona Virus" exact="Disease" post="2019) COVID-19 pandemic [1]. More data has accumulated since"/>
 <result pre="till March 23, 2020 using the keywordsCOVID-19, treatment of coronavirus," exact="COVID" post="19 and following terms; chloroquine, hydroxychloroquine, ibuprofen, ACE-inhibitors or"/>
 <result pre="following terms; chloroquine, hydroxychloroquine, ibuprofen, ACE-inhibitors or angiotensin receptor blockers," exact="cardiovascular disease," post="diarrhoea, liver, testis and gastrointestinal disease.We also accessed the"/>
 <result pre="reducing endocytosis of virus by stabilising the lysosomes, inhibiting the" exact="viral" post="replication, and inducing the production of non-infectious particles by"/>
 <result pre="anti-inflammatory effects by inhibiting the release of proinflammatory cytokines, especially" exact="tumor" post="necrosis factor-alpha which may ameliorate the immune reaction seen"/>
 <result pre="necrosis factor-alpha which may ameliorate the immune reaction seen with" exact="viral" post="infections. In vitro activity of chloroquine (CQ) has been"/>
 <result pre="been demonstrated against several viruses including Vesicular Stomatitis virus [4]," exact="Mouse" post="Hepatitis virus, Nipah virus, Ebola virus, Influenza virus, and"/>
 <result pre="demonstrated against several viruses including Vesicular Stomatitis virus [4], Mouse" exact="Hepatitis" post="virus, Nipah virus, Ebola virus, Influenza virus, and more"/>
 <result pre="and more recently, SARS coronavirus [5,6]. However, except for human" exact="immunodeficiency" post="virus and hepatitis C virus, these effects have not"/>
 <result pre="SARS coronavirus [5,6]. However, except for human immunodeficiency virus and" exact="hepatitis" post="C virus, these effects have not been replicated in"/>
 <result pre="in clinical studies in humans. CQ did not prevent influenza" exact="infection" post="in a randomized, double-blind, placebo-controlled clinical trial [7]. Further,"/>
 <result pre="[7]. Further, there was no effect on patients with dengue" exact="infection" post="in a randomized controlled trial [8]. Of concern was"/>
 <result pre="observation that despite having antiviral activity in vitro, CQ increased" exact="viral" post="replication and exacerbated fever in animal models of chikungunya"/>
 <result pre="increased viral replication and exacerbated fever in animal models of" exact="chikungunya" post="virus infection [9]. Also, patients with chikungunya virus infection"/>
 <result pre="viral replication and exacerbated fever in animal models of chikungunya" exact="virus infection" post="[9]. Also, patients with chikungunya virus infection had more"/>
 <result pre="replication and exacerbated fever in animal models of chikungunya virus" exact="infection" post="[9]. Also, patients with chikungunya virus infection had more"/>
 <result pre="animal models of chikungunya virus infection [9]. Also, patients with" exact="chikungunya" post="virus infection had more chronic arthralgia when treated with"/>
 <result pre="models of chikungunya virus infection [9]. Also, patients with chikungunya" exact="virus infection" post="had more chronic arthralgia when treated with CQ vs."/>
 <result pre="of chikungunya virus infection [9]. Also, patients with chikungunya virus" exact="infection" post="had more chronic arthralgia when treated with CQ vs."/>
 <result pre="infection [9]. Also, patients with chikungunya virus infection had more" exact="chronic" post="arthralgia when treated with CQ vs. those treated with"/>
 <result pre="[11]. Against this background, CQ was evaluated in SARS CoV-2" exact="infection" post="and showed very good in vitro efficacy [12]. The"/>
 <result pre="when nonsteroidal anti-inflammatory drugs (NSAIDs) were used in patients with" exact="pneumonia" post="[19]. 4.1 Practical recommendation based on current evidence Overall,"/>
 <result pre="not mandatory, to avoid ibuprofen and other NSAIDs in COVID-19" exact="infection" post="and use acetaminophen instead for control of fever and"/>
 <result pre="CoV-2 as well as other coronaviruses and is expressed in" exact="type 2" post="alveolar epithelial cells and endothelium. The S-glycoprotein on the"/>
 <result pre="as other coronaviruses and is expressed in type 2 alveolar" exact="epithelial" post="cells and endothelium. The S-glycoprotein on the surface of"/>
 <result pre="reduced rates of death and endotracheal intubation in patients with" exact="viral pneumonia" post="who were continued on ACE inhibitors [21]. Mice with"/>
 <result pre="rates of death and endotracheal intubation in patients with viral" exact="pneumonia" post="who were continued on ACE inhibitors [21]. Mice with"/>
 <result pre="with an angiotensin receptor blocker, losartan [22].As far as CVID-19" exact="infection" post="is concerned, the data on RAS activation or the"/>
 <result pre="data on RAS activation or the effect of its blockadeis" exact="limited" post="at present. Hypokalaemia and hypertension? could be a marker"/>
 <result pre="incidence of hypokalaemia has been reported in patients with COVID-19" exact="infection" post="[23]. Despite these small studies suggesting the benefit of"/>
 <result pre="thiazolidinediones have also been shown to do the same [25,26]." exact="Increased" post="expression of ACE2 could theoretically increase the risk of"/>
 <result pre="Increased expression of ACE2 could theoretically increase the risk of" exact="infection" post="with SARS CoV-2. This could be a concern in"/>
 <result pre="SARS CoV-2. This could be a concern in people with" exact="diabetes" post="who are at already elevated risk of infections because"/>
 <result pre="people with diabetes who are at already elevated risk of" exact="infections" post="because of many other factors.However, there is no evidence"/>
 <result pre="In a retrospective analysis of 112 COVID-19 hospitalised patients with" exact="cardiovascular disease" post="in Wuhan, there was no significant difference in the"/>
 <result pre="a retrospective analysis of 112 COVID-19 hospitalised patients with cardiovascular" exact="disease" post="in Wuhan, there was no significant difference in the"/>
 <result pre="European Society of Cardiology Council on Hypertension, European Society of" exact="Hypertension" post="and American Heart Association [[28], [29], [30]]. 6 Extrapulmonary"/>
 <result pre="of Cardiology Council on Hypertension, European Society of Hypertension and" exact="American" post="Heart Association [[28], [29], [30]]. 6 Extrapulmonary manifestations ACE-2"/>
 <result pre="Cardiology Council on Hypertension, European Society of Hypertension and American" exact="Heart" post="Association [[28], [29], [30]]. 6 Extrapulmonary manifestations ACE-2 receptor,"/>
 <result pre="ACE-2 receptor expression has also been seen in bile duct" exact="epithelial" post="cells. Liver function test abnormalities have been observed in"/>
 <result pre="test abnormalities have been observed in patients with COVID-19 [34]." exact="Steatosis" post="and liver injury have been reported [35]. These could"/>
 <result pre="virus or adverse effects of drugs. 6.2 Kidneys Patients with" exact="chronic" post="kidney and those who have received renal transplant are"/>
 <result pre="have received renal transplant are at increased risk of COVID-19" exact="infection" post="and severity. Moreover, there are frequent renal function abnormalities"/>
 <result pre="there are frequent renal function abnormalities and increased incidence of" exact="acute" post="kidney injury in patients with COVID-19.It is not known"/>
 <result pre="are frequent renal function abnormalities and increased incidence of acute" exact="kidney injury" post="in patients with COVID-19.It is not known yet whether"/>
 <result pre="or is a direct nephrotoxic action of virus. Patients with" exact="acute" post="kidney injury have a higher mortality and renal function"/>
 <result pre="is a direct nephrotoxic action of virus. Patients with acute" exact="kidney injury" post="have a higher mortality and renal function monitoring should"/>
 <result pre="of managing these patients. 6.3 Cardiovascular system Patients with underlying" exact="cardiovascular disease" post="are among the highest risk individuals for severe COVID-19"/>
 <result pre="managing these patients. 6.3 Cardiovascular system Patients with underlying cardiovascular" exact="disease" post="are among the highest risk individuals for severe COVID-19"/>
 <result pre="disease are among the highest risk individuals for severe COVID-19" exact="disease" post="and death [36]. Cardiac troponin Ilevels are significantly increased"/>
 <result pre="highest risk individuals for severe COVID-19 disease and death [36]." exact="Cardiac" post="troponin Ilevels are significantly increased in patients with severe"/>
 <result pre="troponin Ilevels are significantly increased in patients with severe SARS-CoV-2" exact="infection" post="compared to those with milder forms of disease [37]."/>
 <result pre="severe SARS-CoV-2 infection compared to those with milder forms of" exact="disease" post="[37]. This may be similar to what is observed"/>
 <result pre="be similar to what is observed in many patients with" exact="acute" post="respiratory illnesses; or it may indicate myocardial injury because"/>
 <result pre="similar to what is observed in many patients with acute" exact="respiratory" post="illnesses; or it may indicate myocardial injury because of"/>
 <result pre="the virus as ACE-2 receptors are widely expressed on cardiomyocytes." exact="American" post="College of Cardiology recommends measuring troponin if the diagnosis"/>
 <result pre="College of Cardiology recommends measuring troponin if the diagnosis of" exact="acute" post="MI is being considered on clinical grounds and an"/>
 <result pre="an abnormal troponin should not be considered evidence for an" exact="acute" post="MI without corroborating evidence [38]. Similarly, patients with COVID-19"/>
 <result pre="acute MI without corroborating evidence [38]. Similarly, patients with COVID-19" exact="infection" post="have elevated natriuretic peptides, significance of which is uncertain."/>
 <result pre="in COVID-19 should not be taken as an indicator of" exact="heart" post="failure. 6.4 Testis Orchitis was reported in infection with"/>
 <result pre="indicator of heart failure. 6.4 Testis Orchitis was reported in" exact="infection" post="with SARS CoV earlier [39]. ACE-2 receptors are present"/>
 <result pre="is not an expected considering the rapidity with which this" exact="disease" post="has emerged and is progressing. We have attempted to"/>
 <result pre="is rapidly evolving. References References 1GuptaR.GhoshA.SinghA.K.MisraA.Clinical considerations for patients with" exact="diabetes" post="in times of COVID-19 epidemicDiabetes Metab Syndr1432020 Mar 1021121232172175"/>
 <result pre="growth of animal virusesArch Gesamte Virusforsch3611972931044335025 3SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of chloroquine on" exact="viral" post="infections: an old drug against today’s diseases?Lancet Infect Dis3112003"/>
 <result pre="A7861981360536096115382 5KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.MaesP.Antiviral activity of chloroquine against human coronavirus OC43" exact="infection" post="in newbornmiceAntimicrob Agents Chemother53820093416342110.1128/AAC.01509-0819506054 6InglotA.D.Comparison of the antiviral activity"/>
 <result pre="10e78510.1371/journal.pntd.000078520706626 9RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.LumF.M.LabadieK.MartinonF.GrasG.LebonP.NgL.F.P.de LamballerieX.Le GrandR.Paradoxical effect of chloroquine treatment in enhancing" exact="chikungunya" post="virus infectionViruses1052018E26810.3390/v10050268pii29772762 10De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.RoquesP.Le GrandR.On chikungunya acute infection and"/>
 <result pre="chloroquine treatment in enhancing chikungunya virus infectionViruses1052018E26810.3390/v10050268pii29772762 10De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.RoquesP.Le GrandR.On" exact="chikungunya" post="acute infection and chloroquine treatmentVector Borne Zoonotic Dis86200883783910.1089/vbz.2008.004918620511 11SavarinoA.Use"/>
 <result pre="treatment in enhancing chikungunya virus infectionViruses1052018E26810.3390/v10050268pii29772762 10De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.RoquesP.Le GrandR.On chikungunya" exact="acute" post="infection and chloroquine treatmentVector Borne Zoonotic Dis86200883783910.1089/vbz.2008.004918620511 11SavarinoA.Use of"/>
 <result pre="in enhancing chikungunya virus infectionViruses1052018E26810.3390/v10050268pii29772762 10De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.RoquesP.Le GrandR.On chikungunya acute" exact="infection" post="and chloroquine treatmentVector Borne Zoonotic Dis86200883783910.1089/vbz.2008.004918620511 11SavarinoA.Use of chloroquine"/>
 <result pre="and chloroquine treatmentVector Borne Zoonotic Dis86200883783910.1089/vbz.2008.004918620511 11SavarinoA.Use of chloroquine in" exact="viral" post="diseasesLancet Infect Dis119201165365410.1016/S1473-3099(11)70092-521550312 12WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and chloroquine effectively inhibit the"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends1412020 Mar 16727310.5582/bst.2020.0104732074550 15SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine or Hydroxychloroquine"/>
 <result pre="related to the use of non-steroidal anti-inflammatory drugs in community-acquired" exact="pneumonia" post="in adult and pediatric patientsJ Clin Med862019E78610.3390/jcm8060786pii31163625 20HoffmannM.Kleine-WeberH.KrügerN.MüllerM.DrostenC.PöhlmannS.The novel"/>
 <result pre="the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in" exact="adult" post="and pediatric patientsJ Clin Med862019E78610.3390/jcm8060786pii31163625 20HoffmannM.Kleine-WeberH.KrügerN.MüllerM.DrostenC.PöhlmannS.The novel coronavirus 2019"/>
 <result pre="target cellsbioRxiv2020202001.31.929042 21HenryC.ZaizafounM.StockE.GhamandeS.ArroligaA.C.WhiteH.D.Impact of angiotensin-converting enzyme inhibitors and statins on" exact="viral" post="pneumoniaSAVE Proc3142018419423 22YangP.GuH.ZhaoZ.WangW.CaoB.LaiC.YangX.ZhangL.DuanY.ZhangS.ChenW.ZhenW.CaiM.PenningerJ.M.JiangC.WangX.Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9"/>
 <result pre="pneumoniaSAVE Proc3142018419423 22YangP.GuH.ZhaoZ.WangW.CaoB.LaiC.YangX.ZhangL.DuanY.ZhangS.ChenW.ZhenW.CaiM.PenningerJ.M.JiangC.WangX.Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced" exact="acute" post="lung injurySci Rep42014702725391767 23Chen D, Li X, Song Q,"/>
 <result pre="diet-induced nonalcoholicsteatohepatitisSci. World J.2014201460340910.1155/2014/603409 27PengY.D.MengK.GuanH.Q.LengL.ZhuR.R.WangB.Y.HeM.A.ChengL.X.HuangK.ZengQ.T.Clinical characteristics and outcomes of 112" exact="cardiovascular disease" post="patients infected by 2019-nCoVZhonghua Xinxueguanbing Zazhi482020 Mar 2E00410.3760/cma.j.cn112148-20200220-00105032120458 28Position"/>
 <result pre="nonalcoholicsteatohepatitisSci. World J.2014201460340910.1155/2014/603409 27PengY.D.MengK.GuanH.Q.LengL.ZhuR.R.WangB.Y.HeM.A.ChengL.X.HuangK.ZengQ.T.Clinical characteristics and outcomes of 112 cardiovascular" exact="disease" post="patients infected by 2019-nCoVZhonghua Xinxueguanbing Zazhi482020 Mar 2E00410.3760/cma.j.cn112148-20200220-00105032120458 28Position"/>
 <result pre="Zazhi482020 Mar 2E00410.3760/cma.j.cn112148-20200220-00105032120458 28Position statement of the ESC Council on" exact="hypertension" post="on ACE-inhibitors and angiotensin receptor blockershttps://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-angMar 11 2020 29ESH"/>
 <result pre="in 2019 novel coronavirusGut2020 Feb 2610.1136/gutjnl-2020-320832pii: gutjnl-2020-320832 34GuanG.W.GaoL.WangJ.W.WenX.J.MaoT.H.PengS.W.ZhangT.ChenX.M.LuF.M.Exploring the mechanism" exact="of liver" post="enzyme abnormalities in patients with novel coronavirus-infected pneumoniaZhonghua Gan"/>
 <result pre="Za Zhi2822020 Feb 20E00210.3760/cma.j.issn.1007-3418.2020.02.002 35XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeThe Lancet Respiratory Medicine202010.1016/S2213-2600(20)30076-X 36YangJ.ZhengY.GouX.PuK.ChenZ.GuoQ.JiR.WangH.WangY.ZhouY.Prevalence of comorbidities"/>
 <result pre="Zhi2822020 Feb 20E00210.3760/cma.j.issn.1007-3418.2020.02.002 35XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeThe Lancet Respiratory Medicine202010.1016/S2213-2600(20)30076-X 36YangJ.ZhengY.GouX.PuK.ChenZ.GuoQ.JiR.WangH.WangY.ZhouY.Prevalence of comorbidities in"/>
 <result pre="findings of COVID-19 associated with acute respiratory distress syndromeThe Lancet" exact="Respiratory" post="Medicine202010.1016/S2213-2600(20)30076-X 36YangJ.ZhengY.GouX.PuK.ChenZ.GuoQ.JiR.WangH.WangY.ZhouY.Prevalence of comorbidities in the novel Wuhan coronavirus"/>
 <result pre="Dis2020 Mar 1210.1016/j.ijid.2020.03.017pii: S1201-9712(20)30136-3 37LippiG.LavieC.J.Sanchis-GomarF.Cardiac troponin I in patients with" exact="coronavirus disease" post="2019 (COVID-19): evidence from a meta-analysisProg Cardiovasc Dis2020 Mar"/>
 <result pre="Mar 1210.1016/j.ijid.2020.03.017pii: S1201-9712(20)30136-3 37LippiG.LavieC.J.Sanchis-GomarF.Cardiac troponin I in patients with coronavirus" exact="disease" post="2019 (COVID-19): evidence from a meta-analysisProg Cardiovasc Dis2020 Mar"/>
 <result pre="and BNP use in COVID-19https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19 39XuJ.QiL.ChiX.YangJ.WeiX.GongE.PehS.GuJ.Orchitis: a complication of severe" exact="acute" post="respiratory syndrome (SARS)Biol Reprod7422006 Feb41041616237152"/>
 <result pre="BNP use in COVID-19https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19 39XuJ.QiL.ChiX.YangJ.WeiX.GongE.PehS.GuJ.Orchitis: a complication of severe acute" exact="respiratory" post="syndrome (SARS)Biol Reprod7422006 Feb41041616237152"/>
 <result pre="use in COVID-19https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19 39XuJ.QiL.ChiX.YangJ.WeiX.GongE.PehS.GuJ.Orchitis: a complication of severe acute respiratory" exact="syndrome" post="(SARS)Biol Reprod7422006 Feb41041616237152"/>
</results>
